Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhi...

全面介紹

Na minha lista:
書目詳細資料
發表在:JACC Heart Fail
Main Authors: Mann, Douglas L., Greene, Stephen J., Givertz, Michael M., Vader, Justin M., Starling, Randall C., Ambrosy, Andrew P., Shah, Palak, McNulty, Steven E., Mahr, Claudius, Gupta, Divya, Redfield, Margaret M., Lala, Anuradha, Lewis, Gregory D., Mohammed, Selma F., Gilotra, Nisha A., DeVore, Adam D., Gorodeski, Eiran Z., Desvigne-Nickens, Patrice, Hernandez, Adrian F., Braunwald, Eugene
格式: Artigo
語言:Inglês
出版: by the American College of Cardiology Foundation. Published by Elsevier. 2020
主題:
Focus Issue: Angiotensin-Neprilysin Inhibition: Novel Insights
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286640/
https://ncbi.nlm.nih.gov/pubmed/32641226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jchf.2020.05.005
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍